Related Experiment Video

Updated: Jan 19, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

11.1K

The hallmarks of oncogenic signaling: From pathways to resistance in cancer therapy

Muhammad Tufail1, Kunxiang Gong2, Bushra Ijaz3

  • 1Cancer Hospital of Shantou University Medical College, Shantou, China.

Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy
|January 17, 2026
PubMed

Insights

Oncogenic signal transduction pathways drive cancer growth and resistance. New therapies aim to overcome these challenges by targeting key molecular mechanisms in cancer progression.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Oncogenic signal transduction pathways are crucial for tumor progression, regulating cell proliferation, survival, angiogenesis, invasion, and immune evasion.
  • Deregulation of these pathways, through genetic mutations or epigenetic modifications, is a hallmark of cancer, enabling uncontrolled cell growth and resistance to apoptosis.
  • Targeted therapies show promise but face challenges from therapeutic resistance and tumor heterogeneity.

Purpose of the Study:

  • To review the molecular mechanisms of oncogenic pathway activation in cancer.
  • To explore the role of these pathways in cancer traits and therapeutic resistance.
  • To highlight advancements in therapeutic strategies targeting these pathways for improved cancer treatment.

Main Methods:

  • Literature review of molecular mechanisms.
  • Analysis of oncogenic pathway contributions to cancer hallmarks.
  • Exploration of therapeutic resistance and novel treatment strategies.

Main Results:

  • Oncogenic pathways are central to cancer development and progression.
  • Therapeutic resistance and tumor heterogeneity are significant obstacles in targeted cancer therapy.
  • Emerging strategies like combination therapies and next-generation inhibitors show potential.

Conclusions:

  • Understanding oncogenic signaling networks is key to improving cancer treatment.
  • Developing strategies to overcome therapeutic resistance is critical for patient outcomes.
  • Continued research into molecular mechanisms and therapeutic advancements is essential for advancing oncology.
Keywords:
Oncogenic signalingcancer resistancehallmarkstherapeutic targetingtumor progression

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.6K
Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

8.3K

Related Concept Videos

Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.4K